Key result
Continuous IV epoprostenol improves hemodynamics and survival in idiopathic and CTD-PAH but fails in PVOD.
Why the study?
The effectiveness and safety profile of intravenous continuous epoprostenol therapy in various types of pulmonary arterial hypertension require comprehensive review.
Does intravenous continuous epoprostenol improve outcomes in patients with pulmonary arterial hypertension?
Does intravenous continuous epoprostenol improve outcomes in patients with pulmonary arterial hypertension?
Intravenous continuous epoprostenol is an effective treatment for specific types of pulmonary arterial hypertension, though it carries risks of side effects and catheter-related complications.
Answers are grounded in this paper and cite their sources.
IV epoprostenol remains cornerstone therapy in severe PAH; leaves open optimal integration with contemporary targeted agents.
Pulmonary arterial hypertension (PAH) is characterized by elevation of pulmonary artery pressure caused by pulmonary vasoconstriction and vascular remodeling, which leads to right heart failure and death. Epoprostenol (prostaglandin I2) has a potent short-acting vasodilator property, and intravenous continuous epoprostenol is therefore used for treatment of PAH. Here we review evidence for the usefulness of intravenous continuous epoprostenol therapy in patients with PAH. Epoprostenol therapy is effective in idiopathic PAH patients and in patients with PAH associated with connective tissue disease, portal hypertension or congenital heart diseases, but it is not effective in patients with pulmonary veno-occlusive disease or pulmonary capillary hemangiomatosis. High-dose epoprostenol therapy markedly improved hemodynamics in some patients with PAH, possibly due to reverse remodeling of pulmonary arteries. This therapy has several side effects and complications such as headache, hypotension and catheter-related infections. Intravenous continuous epoprostenol is an effective treatment, but there are still some problems to be resolved.
No takes yet. Share an insight, caveat, or question.
Akagi et al. (2015) conducted a review in Pulmonary Arterial Hypertension. Epoprostenol was evaluated. Continuous intravenous epoprostenol therapy improves hemodynamics and survival in idiopathic PAH and PAH associated with connective tissue disease, but is not effective in pulmonary veno-occlusive disease.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: